About us
Our Mission
To be the premier clinical research organization providing early phase Clinical Development services to the biotechnology industry
Our Focus
Ce3 provides support and services exclusively to biotech companies. We specialize in early phase oncology development, and can manage your studies from First In Human (FIH) to accelerated approval.
A specialized CRO for biotechs
We know and understand the biotech environment! Our experience allows us to quickly adapt and deliver on the evolving needs and new requests that are inherent to growing companies.
Our high-touch, proactive approach to clinical trial execution, coupled with our refined processes and technology, allow Ce3 to support clients in the most cost-effective and efficient manner – enabling you to have access to your data early to make the necessary data-driven decisions throughout the study.
Our goal is to deliver quality data faster, easier, and better than our competitors to facilitate timely decisions to meet biotech and investor needs.
Our success is supported by:
- Infrastructure and streamlined processes that allow flexibility and customization
- Tools and technology to create efficiencies and promote cost savings
- Experience needed to provide creative solutions and risk mitigation
- Streamlined communications and transparency to simplify client interactions and oversight
- Our partnership philosophy and team approach
- The leadership required to manage and coordinate teams to deliver on time with quality
Our specialty is oncology
Early phase oncology studies require agility, customization, and attention to detail. Our team is responsive and adept at managing the inevitable challenges inherent to clinical trial.
The evolving drug development paradigm in oncology is resulting in more complex study designs. Now more than ever, Sponsors need a partner that can be flexible and nimble – not rigid or bureaucratic. The ability to be flexible is central to every aspect of our business. Whether your regulatory strategy is to achieve breakthrough designation, fast track or accelerated approval, we will align our operations to support your goals.
Our oncology experience includes:
- Immuno-oncology (inclusive of cell and gene therapies)
- Hematologic Malignancies
- Solid Tumors
Ce3’s memberships include:
Meet the team
Our leadership and infrastructure support ingenuity, transparency, and excellence.
Holly Coulter
President and CEO
Timothy Garrelts
Chief Operating Officer
Deborah Church MD
Chief Medical Officer
Susan Albert BSN, MBA
Head of Strategic Operations and Relationships
Patricia Edwards BSN
Director, Clinical Operations
Melanie Dyer
Director, Data Management
Lydia King PhD
Director, Biostatistics
Darshan Kansagara CSSBB
Director, Clinical Programming
History
Since inception, Ce3 has concentrated on thoroughly understanding the needs of small biotechnology companies and has offered a more collaborative approach with quality services and cost-effective solutions to support our clients’ regulatory and investor goals. We have refined and leveraged our tools and skills to easily accommodate the special requests and customization required by the dynamic biotech environment.
